CoChat

Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2

Open access

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The in vivo binding of clinical dose of venlafaxine on norepinephrine transporter has been questioned because venlafaxine has higher in vitro affinity to serotonin transporter than that to norepinephrine transporter. Although serotonin transporter occupancy of clinically relevant doses of venlafaxine has been reported, there has been no report of norepinephrine transporter occupancy in the human brain. METHODS: This was an open-label, single center, exploratory positron emission tomography study. Twelve major depressive disorder patients who had responded to venlafaxine extended-release and 9 control subjects were recruited. Each subject participated in one positron emission tomography measurement with [18F]FMeNER-D2. Binding potential in brain was quantified by the area under the curve ratio method with thalamus as target and white matter as reference regions. The difference of binding potential values between control and patient groups divided to 2 dose ranges were evaluated. Norepinephrine transporter occupancy (%) for all the major depressive disorder patients was calculated using mean binding potential of control subjects as baseline. The relationships between dose or plasma concentration of total active moiety and occupancies of norepinephrine transporter were also estimated. RESULTS: The binding potential of the patient group with 150 to 300 mg/d was significantly lower than that in the control subjects group (P = .0004 < .05/2). The norepinephrine transporter occupancy (8-61%) increased in a dose-dependent manner although a clear difference beyond 150 mg/d was not observed. CONCLUSIONS: This study demonstrates that clinically relevant doses of venlafaxine extended-release block the norepinephrine transporter of the major depressive disorder patient's brain. The data support the notion that the antidepressant effect of venlafaxine involves a combination of serotonin transporter and norepinephrine transporter blockades.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyz003

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Averaged binding potential (BPND) images of control subjects and major depressive disorder (MDD) patients for 2 dose ranges.
Figure 1. Averaged binding potential (BPND) images of control subjects and major depressive disorder (MDD) patients for 2 dose ranges.CC BY-NC · PubMed Central
Figure 2. Comparison of binding potential (BPND) values between control subjects as baseline (n = 9) and major depressive disorder (MDD) patients groups divided into 2 dose ranges (each n = 6). BPND of patients groups with 150–300 mg/d was significantly lower than that in the control subjects group (P = .0004).
Figure 2. Comparison of binding potential (BPND) values between control subjects as baseline (n = 9) and major depressive disorder (MDD) patients groups divided into 2 dose ranges (each n = 6). BPND of patients groups with 150–300 mg/d was significantly lower than that in the control subjects group (P = .0004).CC BY-NC · PubMed Central
Figure 3. Relationship between dose of venlafaxine extended release (ER) and norepinephrine transporter (NET) occupancy for major depressive disorder (MDD) patients. Solid line: dose of venlafaxine ER required to induce 50% of NET occupancy (Kd:dose) was 248 mg/d. R = 0.68. Dashed line: Kd:dose was 130 mg/d and maximal NET occupancy by dose (Omax:dose) was 71%. R = 0.71.
Figure 3. Relationship between dose of venlafaxine extended release (ER) and norepinephrine transporter (NET) occupancy for major depressive disorder (MDD) patients. Solid line: dose of venlafaxine ER required to induce 50% of NET occupancy (Kd:dose) was 248 mg/d. R = 0.68. Dashed line: Kd:dose was 130 mg/d and maximal NET occupancy by dose (Omax:dose) was 71%. R = 0.71.CC BY-NC · PubMed Central
Figure 4. Relationship between plasma concentration of total active moiety of venlafaxine and norepinephrine transporter (NET) occupancy for major depressive disorder (MDD) patients. Plasma concentration of total active moiety was defined as sum of venlafaxine and its main active metabolite O-desmethylvenlafaxine. Solid line: plasma concentration of total active moiety required to induce 50% of NET occupancy (Kd:conc) was 671 ng/mL. R = 0.61. Dashed line: Kd:conc was 246 ng/mL and maximal NET occupancy by concentration (Omax:conc) was 62%. R = 0.71.
Figure 4. Relationship between plasma concentration of total active moiety of venlafaxine and norepinephrine transporter (NET) occupancy for major depressive disorder (MDD) patients. Plasma concentration of total active moiety was defined as sum of venlafaxine and its main active metabolite O-desmethylvenlafaxine. Solid line: plasma concentration of total active moiety required to induce 50% of NET occupancy (Kd:conc) was 671 ng/mL. R = 0.61. Dashed line: Kd:conc was 246 ng/mL and maximal NET occupancy by concentration (Omax:conc) was 62%. R = 0.71.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 72

Metadata

Authors
Arakawa, R., Stenkrona, P., Takano, A., Svensson, J., Andersson, M., Nag, S., Asami, Y., Hirano, Y., Halldin, C., & Lundberg, J.
Affiliations
  • Region Stockholm (SE)
  • Pfizer (Japan) (JP)
Corresponding author
Arakawa, Ryosuke
Venue
International Journal of Neuropsychopharmacology
Published
2019-01-11
Volume
22
Issue
4
Pages
278-285
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2910200143
Cited by
70
References
46
Citations by year
2026: 6 · 2025: 8 · 2024: 9 · 2023: 3 · 2022: 8 · 2021: 27 · 2020: 8 · 2019: 1
FWCI
6.81
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Swedish Research Council
  • Pfizer Japan Inc.
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
venlafaxine extended release, norepinephrine transporter, major depressive disorder, binding potential, serotonin transporter, antidepressant mechanism, dose-dependent binding
MeSH terms
Serotonin and Noradrenaline Reuptake Inhibitors, Venlafaxine Hydrochloride, Adult, Aged, Brain, Delayed-Action Preparations, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Morpholines, Positron-Emission Tomography, Norepinephrine Plasma Membrane Transport Proteins, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.